Ramipril (ramipril): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Ramipril 1.25 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 1.25mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 1.25mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg/5ml Oral Solution

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

- manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

- diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

- Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria

- Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor

- Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.


Route of administration: Oral
Molecule: ramipril

Patients' opinions on Ramipril

In brief

General satisfaction level: 9.20/10 Learn more

Treatment's effectiveness: 9.20/10 Learn more

Ease of use: 9.80/10 Learn more

Adherence to prescription: 8.80/10 Learn more

Detected side effects: 4.00/10 Learn more

Improvement in the quality of life: 9.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
nineteen_gale
on 25/02/2019

I have been to Ramipril for a number of years now. Was initially started off as 10 mg capsules. it was then reduced to 5 mg and after further, review I am now on 7,5 mg. They suit me very well, keep my blood pressure stable, and as yet, I have not suffered from any side effects. I have to have a regular check on my kidney function tests, as it can damage your kidney. my kidney function tests have been fine up to now and am due for another check next week

Is any one else on this medication? Would like your vies on the same. 

Thanks

nineteen_gale

Your message

Members using this Ramipril

Conditions related to this medication

See the fact sheet
See the fact sheet
See the fact sheet